Answers for practitioners considering DRS.

DRS serves licensed healthcare practitioners — physicians, chiropractors, nurse practitioners, and integrative clinics adopting regenerative and functional medicine. As of 2026 we support 1,850+ providers across all 50 US states.

Founded in 2016, DRS is entering its 10th year advising clinics on biologics, devices, PPE sourcing, and AI-driven peptide protocols.

Yes. In 2026 we run quarterly virtual clinical bootcamps plus in-person device certification days. Over 1,200 providers have completed DRS training since inception.

Zimmer Z Wave (radial shockwave), focused ECSWT/LiSWT systems, Class IV High Power Laser Therapy (HPLT), IR Low-Level Laser Diode (LLLT), Eufoton LASEmaR 1500, LadyLift® / EndoLift®, and fractional dermal infusion / microneedling platforms.

Radial pulse (RPT) is versatile and cost-effective for musculoskeletal and aesthetic work. Focused ECSWT reaches deeper tissue and is preferred for urologic, cardiovascular, and advanced orthopedic indications. Most 2026 buyers start with radial and add focused as case volume grows.

All devices we distribute carry current FDA 510(k) clearances for their marketed indications. Off-label use is at practitioner discretion within standard of care.

Typical lead time is 3–5 weeks for shockwave and Class IV laser systems, 2–3 weeks for LLLT diode units. Financing and clinical training are included.

Yes — all platforms ship with manufacturer warranty (typically 2 years) plus DRS post-sale clinical protocol support at no additional cost for the first 12 months.

All MSC biologics are obtained from donated, full-term, live-birth pregnancies. Donors undergo comprehensive screening in accordance with FDA requirements and 21 CFR 1271 to minimize disease transmission risk.

MSC exosomes are 30–150 nm extracellular vesicles carrying growth factors and RNA. Wharton's Jelly is a structural umbilical-cord matrix rich in hyaluronic acid, pericytes, and MSCs. Exosomes signal; Wharton's Jelly scaffolds — many 2026 protocols combine both.

Cryopreserved products ship on dry ice with a 72-hour thermal buffer and require −80°C long-term storage. Lyophilized exosome preparations are stable at 2–8°C for up to 24 months.

Yes. Combining LrPRP or PRFM with amniotic allografts or exosomes is a common 2026 protocol for tendon, joint, and aesthetic applications — the autologous concentrate provides platelet-derived growth factors while the allograft adds structural matrix.

N95 and KN95 respirators, surgical masks, nitrile gloves, gowns, face shields, hand sanitizer, injection supplies, procedure trays, and FDA-authorized rapid antigen COVID tests — all through vetted US-based partners.

Licensed US healthcare providers and organizations only. DRS is a Texas Medical Device Distributor (#1002308).

Yes. In 2026 we support multi-site orders with staggered fulfillment, direct-to-clinic shipping, and quarterly restock scheduling.

We source injection consumables (syringes, needles, vials, alcohol prep) and refer peptide compounding to our 503A/503B partner network — all shipments require an active prescription.

Dr. Peptide is a collective intelligence built from 16 specialized AI agents and refined by 75+ peptide-savvy practitioners (up from 50 in 2024). As of 2026 it draws on 3,400+ curated clinical studies to deliver personalized protocol recommendations.

PepEdHub is the free evidence library and clinical tool set for providers — 95+ peptide profiles, 3,400+ studies, 110+ protocols, and 14 clinical tools in 2026. PeptideProtocols.ai generates personalized peptide protocols using Dr. Peptide and left closed beta in Q1 2026.

No. It is a clinical decision-support tool. Every recommendation includes source citations, contraindications, and monitoring guidance for the prescribing provider to review.

Yes. PeptideProtocols.ai is HIPAA-compliant, hosts PHI in encrypted, audited infrastructure, and never uses patient data to train third-party foundation models.

Focused ECSWT / LiSWT: vasculogenic erectile dysfunction, Peyronie's disease, chronic pelvic pain, calcific rotator cuff, and deep tendinopathy. Radial (RPT): plantar fasciitis, Achilles and patellar tendinopathy, myofascial pain, and cellulite / body remodeling.

Absolute: over active malignancy in the treatment field, over lung tissue with focused energy, in patients on therapeutic anticoagulation with bleeding risk, over open growth plates in children, and over gravid uterus. Relative: pacemakers / implanted devices in the treatment field, coagulopathy, and acute infection.

A $65 – $95k focused system typically breaks even at 22 – 32 completed cash-pay packages ($2,800 – $4,500 per ED package in 2026 median markets). Most practices reach breakeven within 4 – 8 months with a modest internal referral funnel.

Prescriber: 4 – 6 hours of protocol training plus one on-site clinical day. Clinical support (RN / MA under delegated protocol): 8 – 12 hours plus 5 supervised sessions before independent operation.

ED and most sexual-wellness indications are cash-pay in the U.S. MSK indications may bill CPT Category III codes 0512T / 0513T; coverage varies widely by payer and region and should be re-verified quarterly.

HPLT (Class IV, 10 – 30 W): musculoskeletal pain, tendinopathy, post-surgical rehab, peripheral neuropathy adjunct, and sports-medicine recovery. LLLT (diode): wound healing, oral mucositis, androgenic alopecia, TMJ dysfunction, and post-procedure recovery.

Do not treat over active malignancy in the treatment field, over the thyroid, over the gravid uterus, or over photosensitive skin conditions or on patients on photosensitizing medications. Eye protection appropriate to wavelength is mandatory for patient and operator.

HPLT units (~$30 – $55k) typically break even at 120 – 180 paid sessions ($75 – $175 per session cash-pay in 2026). LLLT diode units are lower capital ($8 – $20k) and are often bundled into aesthetic and hair-loss packages rather than billed per session.

Prescriber sign-off on treatment plans plus 4 hours of device training. Clinical staff: 6 – 10 hours plus 3 – 5 observed sessions. WALT dosage tables and manufacturer protocol sheets are the reference standards.

Most aesthetic, sports-recovery, and hair-loss indications are cash-pay. Post-surgical rehab and pain-management indications may bill under 97026 (infrared) or 97039 (unlisted modality) depending on payer; documentation of medical necessity is essential.

GLP-1 / dual / triple agonists (semaglutide, tirzepatide, retatrutide) for obesity and cardiometabolic risk; select GH secretagogues (per current compounding permissions) for age-related somatopause under specialist oversight; targeted repair peptides (BPC-157, TB-500) remain education-tier only in the U.S.

GLP-1 class: personal or family history of medullary thyroid carcinoma or MEN 2, prior pancreatitis, active gallbladder disease, severe gastroparesis, and pregnancy / lactation. All classes: unverified 'research-only' sourcing, patients unable to demonstrate injection competency, and any peptide not on current FDA-permitted compounding lists.

GLP-1 programs typically add $400 – $900 monthly revenue per active patient (drug + visit fees, cash-pay) at 60 – 80% gross margin depending on pharmacy relationships. Program launch pays back staff training cost inside the first 30 – 60 patients.

Six-week structured curriculum: MA / RN ~18 hours; NP / PA ~30 hours; prescriber ~40 hours (see our full staff-training article). Quarterly refresh required because the FDA compounding permitted list changes.

Compounded peptides are cash-pay. Branded GLP-1s (Wegovy, Zepbound) may be covered under obesity or cardiometabolic indications depending on payer and PBM; expect step therapy and prior-authorization requirements. Practices should keep a coverage-check workflow current.

Autologous PRP for orthopedic tendinopathy, aesthetic rejuvenation, and hair loss. Amniotic allografts for wound care, ophthalmic reconstruction, and orthopedic soft-tissue augmentation. Perinatal MSC and exosome products only within the U.S. regulatory framework — see our legal-issues article for scope.

Active malignancy at the treatment site, active infection, uncontrolled autoimmune flare, pregnancy for non-emergent procedures, and patients on immunosuppression without specialist coordination. Product-specific contraindications appear on each Certificate of Analysis.

PRP: $600 – $1,500 per session; typical program adds $8 – $25k monthly. Amniotic allograft wound-care programs are payer-mix dependent; orthopedic and aesthetic amniotic use is typically cash-pay at $1,200 – $3,500 per case.

PRP: 8 – 12 hours plus 5 supervised draws / spins / injections. Amniotic allografts: 4 – 8 hours plus manufacturer application training. All staff must be trained on cold-chain handling, lot documentation, and adverse-event reporting.

Autologous PRP for orthopedic use is cash-pay for most payers; skin-substitute amniotic allografts for chronic DFU / VLU wounds may be covered under Medicare and select commercial payers with LCD-specific documentation. Cash-pay is the default for aesthetic and sexual-wellness use.

Five in 2026: urology, sexual wellness, medical aesthetics, orthopedics & sports medicine, and dermatology. Each specialty page (e.g. /specialties/urology) lists the devices, biologics, and protocols we deploy plus an evidence snapshot and the publications that map to that specialty.

Every publication on /publications tags the specialties it applies to. On each specialty page you'll see a 'Publications relevant to this specialty' block that surfaces only the studies and white papers whose related-links point to that specialty, along with a short 'why it's relevant' note.

Yes — that is our most common engagement. We combine specialty-specific device selection, biologic sourcing, protocol templates, staff training, and ROI modeling so a urology, aesthetics, or orthopedic practice can launch a regenerative service line without disrupting existing workflow.

Yes. Many DRS partners run overlapping programs — for example ECSWT shared between urology and orthopedics, or exosome and MSC biologics shared between aesthetics and dermatology. We map device and biologic utilization across specialties so shared assets carry their weight.

Our /publications page indexes the 3,400+ curated studies powering PepEdHub, plus DRS-authored white papers on peptide safety, exosome sourcing, and shockwave outcomes. Each publication cross-links to the specialty pages it applies to and to the relevant device or biologic listing.

The library carries a visible 'Updated' date and is refreshed on a rolling basis — the latest curation is dated July 2026. New evidence is added as it clears our internal review; retired or superseded citations are removed rather than left stale.

In 2026 we publish 2–4 long-form clinical guides per month, including quarterly State of Regenerative surveys and monthly device outcome roundups. New posts appear in our /rss.xml and /atom.xml feeds alongside publication updates.

Yes. /rss.xml and /atom.xml carry blog posts plus publications updates in a single feed, so a reader like Feedly or Inoreader surfaces both channels together.

Yes — licensed providers can submit anonymized case reports through the Contact page. Accepted submissions run in the RegenTruth blog with author attribution.

Selected 2026 clinical guides and device certification courses are AMA PRA Category 1 accredited through our academic partners. CME status is noted at the top of each eligible post.